Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT
Launched by TURKU UNIVERSITY HOSPITAL · Jan 12, 2011
Trial Information
Current as of May 30, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the benefits of a special imaging technique called FDG-PET/CT in women newly diagnosed with advanced types of ovarian cancer, peritoneal cancer, or fallopian tube cancer. The goal is to see if this imaging method helps doctors better understand the stage of the cancer and how well it responds to chemotherapy compared to a standard imaging method called contrast-enhanced CT. The trial will also look at blood tests that measure certain markers related to cancer to see how they compare to the imaging results.
To participate in this trial, women between the ages of 18 and 79 who have recently been diagnosed with advanced ovarian or related cancers may be eligible, provided they haven't had diabetes or another previous cancer. Participants will undergo the FDG-PET/CT scan before surgery, after initial chemotherapy treatments, and shortly after finishing their chemotherapy. They will also have their blood tested regularly to monitor their cancer markers. This study is currently active but not recruiting new participants, and it aims to improve the way doctors assess and treat these cancers.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Newly diagnosed patients with advanced epithelial ovarian, primary peritoneal cancer or fallopian tube cancer.
- • age 18-79 years
- • informed concent
- Exclusion Criteria:
- • diabetes (for PET/CT analyses)
- • previous cancer
About Turku University Hospital
Turku University Hospital (TYKS) is a leading academic medical center located in Turku, Finland, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a key institution within the University of Turku, TYKS integrates cutting-edge medical education with state-of-the-art clinical services, offering a broad spectrum of specialized care. The hospital actively participates in clinical trials, facilitating the translation of scientific discoveries into practical treatments, and enhancing patient outcomes. With a multidisciplinary approach and a focus on collaboration, TYKS aims to contribute significantly to the global medical community through its rigorous research initiatives and commitment to patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Turku, , Finland
Patients applied
Trial Officials
Johanna Hynninen, Adj prof
Study Director
Turku University hospital, Department of Obstetrics and Gynecology
Johanna Hynninen, MD, PhD
Principal Investigator
Turku University hospital, Department of Obstetrics and Gynecology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials